The effect of hormonal contraceptives combined with vitamin D3 supplements on sexual dysfunction in women with polycystic ovary syndrome: a randomized double-blind placebo-controlled trial.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

The present study aimed to assess the effect of oral contraceptive pills (OCPs) and vitamin D3 on sexual dysfunction in women with PCOS and vitamin D3 deficiency.

Why It Was Studied

Polycystic ovary syndrome (PCOS) is characterized by reproductive and endocrine abnormalities.

Who Took Part

The age groups tagged for this paper are young adults and adults, women only.

The Female Sexual Function Index (FSFI) and Beck Depression Inventory (BDI) questionnaires were filled out for all participants and their serum levels of vitamin D3 were measured.

Women with PCOS and vitamin D3 deficiency were divided into 2 equal groups (A and B) with a table of random numbers (n = 35/ each).

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Neither the participants nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.

This randomized double-blind placebo-controlled clinical trial was conducted in Iran between January and April 2019.

Vitamin D3 level and sexual function were assessed in both groups at 3 and 6 months after taking OCP.

What Was Measured

The subject headings attached to it are Polycystic Ovary Syndrome, Cholecalciferol, Sexual Dysfunction, Physiological, Iran, Dietary Supplements and Contraceptives, Oral, Hormonal.

The authors tagged it with the keywords OCP, PCOS and Vitamin D.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2025 (Archives of gynecology and obstetrics), a journal based in Germany.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.